H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Acrivon Therapeutics to $22 from $20 and keeps a Buy rating on the shares after the company reported Q1 results and provided corporate updates. The company ended Q1 with $110M in cash and equivalents, notes the firm, which estimates that the company’s pro-forma cash is sufficient to fund operations into the second half of 2026 and cites lower than anticipated operating expenses for the firm’s raised price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Acrivon Therapeutics downgraded to Neutral from Buy at Ladenburg
- Acrivon Therapeutics price target raised to $25 from $18 at BMO Capital
- Acrivon Therapeutics price target lowered to $22 from $26 at JonesResearch
- Acrivon Therapeutics Inc trading resumes
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue